You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

platinum-refractory, platinum-resistant, ovarian cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer Trial in Orlando, Albuquerque

Recruiting
  • Platinum-resistant Ovarian Cancer
  • +6 more
  • olvimulogene nanivacirepvec
  • +3 more
  • Orlando, Florida
    AdventHealth Cancer Institute
Sep 1, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Completed
Has Results
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +8 more
  • Bevacizumab
  • Irinotecan Sucrosofate
  • Chicago, Illinois
    Northwestern University
Dec 21, 2022

Malignant Ovarian Epithelial Tumor, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma Trial in

Recruiting
  • Malignant Ovarian Epithelial Tumor
  • +9 more
  • Akt/ERK Inhibitor ONC201
  • +2 more
  • Detroit, Michigan
    Barbara Ann Karmanos Cancer Institute
May 10, 2022

Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer Trial in Rochester, Helsinki (TILT-123, Pembrolizumab)

Recruiting
  • Platinum-refractory Ovarian Carcinoma
  • Platinum-resistant Ovarian Cancer
  • TILT-123
  • Pembrolizumab
  • Rochester, Minnesota
  • +1 more
Aug 12, 2022

Ovarian Cancer, Relapsed or Refractory, Chiauranib Trial in Shanghai (chiauranib, Placebo, Paclitaxel)

Recruiting
  • Ovarian Cancer
  • +3 more
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 7, 2022

Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal

Recruiting
  • Platinum-Refractory Fallopian Tube Carcinoma
  • +11 more
  • Copanlisib Hydrochloride
  • +4 more
  • Aurora, Colorado
  • +2 more
Dec 8, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +8 more
  • Durvalumab
  • Tremelimumab
  • Houston, Texas
    M D Anderson Cancer Center
Jul 19, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Active, not recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +11 more
  • Aldesleukin
  • +3 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Jul 13, 2022

Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in New Haven, Baltimore (Ixabepilone,

Active, not recruiting
  • Epithelial Ovarian Cancer
  • +2 more
  • New Haven, Connecticut
  • +1 more
Jan 11, 2023

Carcinoma, Ovarian Epithelial, Ovarian Tumors, Fallopian Tube Tumors Trial in Iowa City (AB-1015)

Recruiting
  • Carcinoma, Ovarian Epithelial
  • +8 more
  • AB-1015
  • Iowa City, Iowa
    U. of Iowa Health Care
Jan 30, 2023

Platinum-resistant Recurrent Clear Cell Ovarian Cancer Trial in Guangzhou (Niraparib, Anlotinib)

Not yet recruiting
  • Platinum-resistant Recurrent Clear Cell Ovarian Cancer
  • Guangzhou, Guangdong, China
    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Nov 21, 2021

Small Cell Carcinoma, NSCLC, Neuroendocrine Tumors Trial in United States (RRx-001, Cisplatin, Etoposide)

Active, not recruiting
  • Small Cell Carcinoma
  • +3 more
  • Palo Alto, California
  • +9 more
May 12, 2022

Ovarian Cancer Trial in Beijing, Jinan (Niraparib)

Recruiting
  • Ovarian Cancer
  • Beijing, China
  • +1 more
Aug 27, 2021

Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma

Active, not recruiting
  • Fallopian Tube Endometrioid Adenocarcinoma
  • +7 more
  • Anetumab Ravtansine
  • +2 more
  • Orange, California
  • +22 more
Oct 22, 2022

Platinum-resistant Ovarian Cancer Trial in China (Mitoxantrone Hydrochloride Liposome, intravenous injection (IV))

Recruiting
  • Platinum-resistant Ovarian Cancer
  • Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)
  • Chongqing, Chongqing, China
  • +6 more
May 31, 2021

Platinum-resistant Ovarian Cancer

Not yet recruiting
  • Ovarian Cancer
  • pegylated liposomal doxorubicin
  • (no location specified)
Aug 2, 2023

Ovarian Cancer Recurrent Trial (Fluzopril Combined With Apatinib)

Not yet recruiting
  • Ovarian Cancer Recurrent
  • Fluzopril Combined With Apatinib
  • (no location specified)
Oct 22, 2023

Ovarian Cancer, Platinum-resistant Ovarian Cancer Trial in Minsk (Gemcitabine, ELENAGEN)

Active, not recruiting
  • Ovarian Cancer
  • Platinum-resistant Ovarian Cancer
  • Minsk, Belarus
    Minsk City Clinical Oncology Center
Jul 27, 2023

BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma Trial in Buffalo, New York (biological, other, drug)

Active, not recruiting
Has Results
  • BRCA1 Gene Mutation
  • +5 more
  • Durvalumab
  • +3 more
  • Buffalo, New York
  • +1 more
Jan 20, 2023

Ovarian High Grade Serous Adenocarcinoma, Platinum-Resistant Ovarian Carcinoma Trial in Atlanta (Atovaquone, Biopsy, Computed

Not yet recruiting
  • Ovarian High Grade Serous Adenocarcinoma
  • Platinum-Resistant Ovarian Carcinoma
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Aug 11, 2023

Ovarian Cancer Trial in France (Pazopanib, Paclitaxel)

Completed
  • Ovarian Cancer
  • Avignon, France
  • +35 more
Feb 23, 2022

Breast Cancer Female, Ovarian Cancer, Gastric Cancer Trial in Bronx (Nivolumab, Ipilimumab)

Terminated
  • Breast Cancer Female
  • +2 more
  • Nivolumab
  • Ipilimumab
  • Bronx, New York
    Hoffman Oncology
Nov 5, 2021

Advanced Solid Tumor, Platinum-resistant Ovarian Cancer Trial (SON-1010)

Not yet recruiting
  • Advanced Solid Tumor
  • Platinum-resistant Ovarian Cancer
  • SON-1010
  • (no location specified)
Mar 10, 2023

Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma Trial in

Unknown status
  • Platinum-resistant Ovarian Cancer
  • +3 more
  • PHI-101 administration
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Jan 16, 2021

Ovarian Carcinoma Trial in New Haven (Sacituzumab govitecan)

Not yet recruiting
  • Ovarian Carcinoma
  • Sacituzumab govitecan
  • New Haven, Connecticut
    Smilow Cancer Hospital at Yale New Haven
Aug 31, 2023